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 Abstract 
 The prevalence of overweight and obesity has reached epidemic proportions worldwide due 
to increasingly pervasive obesogenic lifestyle changes. Obesity poses unprecedented indi-
vidual, social, and multidisciplinary medical challenges by increasing the risk for metabolic 
diseases, chronic organ failures, and cancer as well as complication rates in the presence of 
acute disease conditions. Whereas reducing excess adiposity remains the fundamental patho-
genic treatment for obese individuals, complex metabolic and lifestyle abnormalities as well 
as weight reduction therapies per se may also compromise the ability to preserve muscle 
function and mass, especially when chronic disease co-exists with obesity. Emerging evidence 
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indicates that low muscle mass and quality have a strong negative prognostic impact in obese 
individuals and may lead to frailty, disability, and increased morbidity and mortality. Aware-
ness of the importance of skeletal muscle maintenance in obesity is however low among cli-
nicians and scientists. The term ‘sarcopenic obesity’ has been proposed to identify obesity 
with low skeletal muscle function and mass, but its utilization is largely limited to the aging 
patient population, and consensus on its definition and diagnostic criteria remains insuffi-
cient. Knowledge on prevalence of sarcopenic obesity in various clinical conditions and pa-
tient subgroups, on its clinical impacts in patient risk stratification, and on effective prevention 
and treatment strategies remain therefore dramatically inadequate. In particular, optimal di-
etary options and medical nutritional support strategies to preserve muscle mass in obese 
individuals remain largely undefined. The European Society for Clinical Nutrition and Metab-
olism (ESPEN) and the European Association for the Study of Obesity (EASO) recognize and 
indicate obesity with altered body composition due to low skeletal muscle function and mass 
(sarcopenic obesity) as a scientific and clinical priority for researchers and clinicians. ESPEN 
and EASO therefore call for coordinated action aimed at reaching consensus on its definition, 
diagnostic criteria, and optimal treatment with particular regard to nutritional therapy. We are 
convinced that achievement of these goals has a strong potential to reduce the burden of 
morbidity and mortality in the rapidly increasing obese patient population. 
 © 2018 The Author(s)
Published by S. Karger GmbH, Freiburg 
 Introduction: What We Know 
 Obesity Epidemic 
 Obesity is a disease characterized by increased adiposity with negative impact on patient 
health, and it is commonly diagnosed by body mass index (BMI) above 30 kg/m 2 (or above 
27.5 kg/m 2 in specific ethnic groups). Its prevalence has rapidly increased worldwide over 
the last three decades, largely due to combined genetic predisposition and profound lifestyle 
changes including sedentary habits and high-calorie dietary intake  [1–3] . In many parts of the 
world, overweight (BMI > 25 kg/m 2 ) and obese individuals currently account for a majority 
of the population  [3–6] ; the proportion is substantially higher in middle- and elderly age 
groups  [7, 8] . This unprecedented shift in body weight paradigms has posed dramatic indi-
vidual, social, economic and healthcare challenges. Obesity is a strong risk factor for meta-
bolic diseases such as metabolic syndrome and type 2 diabetes as well as atherosclerosis and 
cardiovascular events  [9, 10] . In addition, obese individuals are at higher risk for many 
chronic and acute diseases involving end-stage organ failures, cancer, and infections  [9–12] . 
For example, overweight and obese patients carry an at least 70% higher risk for coronary 
disease and a 20–50% higher risk of developing wound infections after colorectal surgery 
compared to normal-weight patients  [13] . Liver steatosis, cirrhosis, and cancer becomes a 
raising challenge for patients with long-standing obesity  [14] . All the above conditions may 
lead to acute complications and hospitalizations. 
 Obesity and Skeletal Muscle 
 Reducing excess adiposity remains the fundamental pathogenic treatment for obese indi-
viduals  [15, 16] . Complex metabolic and lifestyle abnormalities  [17–22] as well as weight 
reduction therapies per se  [23] may however also compromise the ability to preserve muscle 
function and mass. Skeletal muscle changes are not uniformly observed in obese individuals, 
and heterogeneous phenotypes may contribute to their underestimation. Indeed a positive 
association between BMI and lean body mass has been reported in general population studies 
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 [23] , and moderate increments in skeletal muscle mass may occur in obesity as a consequence 
of higher postural and ambulatory muscle work as well as potential direct anabolic effects of 
higher dietary intake of calorie proteins. It is however increasingly clear that profound 
skeletal muscle metabolism changes may occur in obesity and may lead to altered body 
composition with higher fat mass and substantial impairment of muscle mass and quality 
 [24–27] . Various complex interrelated mechanisms may contribute to these changes. 
 Metabolic and Lifestyle Changes 
(1)  Primary Metabolic Abnormalities: Clustered metabolic derangements including systemic 
and muscle oxidative stress, inflammation and insulin resistance may occur in obesity 
 [17–20] due to various causes that primarily include i) excess nutrient availability and 
tissue delivery, particularly saturated fat  [28] and glucose  [29] as well as ii) adipose 
tissue dysfunction upon activation of maladaptive responses in the presence of enhanced 
demand for lipid storage  [30] . These alterations are at least in part causally interrelated 
and have a strong muscle-catabolic potential  [31] ; they can also promote a typical 
‘anabolic resistance’ state in skeletal muscle, meaning that the response of muscle protein 
synthesis to nutrients is blunted  [24–27] . 
(2)  Ectopic Muscle Fat Accumulation: Muscle lipid accumulation commonly occurs  [30] as a 
result of insufficient adipose tissue expansion in the face of excess lipid availability  [32] ; 
convincing evidence has long demonstrated the close association of skeletal muscle lipid 
content with tissue and systemic insulin resistance  [30, 33] . Mechanisms mediating 
metabolic lipotoxicity are complex and appear to include direct pro-oxidative and 
inflammatory activities  [28] as well as accumulation of metabolically toxic lipid moieties 
such as diacylglycerol and ceramides  [34] . Recent evidences show that ectopic lipid 
deposition may also compromise muscle protein turnover  [35] . 
(3)  Mitochondrial Dysfunction:  Mitochondrial changes are not invariably observed in obese 
skeletal muscle until relatively late stages  [21, 22] . Their onset may however exacerbate 
oxidative stress and related metabolic cascades leading to insulin resistance and 
catabolism  [21, 22] . Potential reduction in ATP production may also directly result in low 
muscle strength and endurance capacity.  
(4)  Stem Cell Dysfunction: Functionally altered muscle stem cells that may undergo adipocyte 
differentiation are increasingly described in the context of complicated obesity and 
muscle fat accumulation  [36–38] , and their potential relevant role in limiting skeletal 
muscle mass maintenance has been proposed. 
(5)  Physical Inactivity:  Low physical activity is one fundamental contributor to positive energy 
balance  [22] . Progressive reduction of physical activity is further observed with disease 
progression due to worsening obesity and its joint and musculoskeletal complications 
 [22] , with direct negative impact on muscle protein turnover and muscle oxidative and 
performance capacity  [39, 40] .  
 Comorbidities and Treatment 
(1)  Cardiometabolic Complications:  Complications such as metabolic syndrome or overt type 
2 diabetes and hyperglycemia are associated with enhanced oxidative stress, 
pro-inflammatory changes, and mitochondrial dysfunction  [21, 29] that commonly cause 
catabolic abnormalities and may independently further muscle alterations. Altered tissue 
perfusion in the presence or absence of clinically relevant atherosclerotic disease as well 
as epicardial fat enlargement may also cause metabolic complications by enhancing ROS 
production and their negative metabolic impact  [41, 42] . 
(2)  Chronic and Acute Complications:  Obesity directly enhances the risk for, or may be 
associated with chronic organ failure syndromes and chronic diseases (including chronic 
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heart failure, chronic kidney disease, chronic obstructive pulmonary disease, obstructive 
sleep apnea syndrome, and cancer) as well as their acute complications  [10–12] . All of 
the above events and conditions may result in heterogeneous sources of inflammation 
and oxidative stress  [43–48] while impairing spontaneous physical activity, thereby 
synergistically enhancing muscle loss and dysfunction  [49] . 
(3)  Surgical and Medical Treatment:  Bariatric procedures are becoming increasingly common 
and almost invariably lead to skeletal muscle catabolism, at least in the initial rapid 
weight loss phase, characterized by profoundly negative energy balance  [50] ; low- or 
very-low-calorie diets are associated with similar qualitative changes although to less 
pronounced degrees  [23, 51] . 
 A multifactorial network of clustered alterations therefore appears to occur in obesity 
that may account for skeletal muscle derangements. While these changes are not inevitable, 
they become increasingly likely in patients with longer obesity duration, complications, and 
comorbidities as well as in elderly individuals that may undergo muscle changes also due to 
aging per se  [52] . Most mechanisms directly reduce muscle anabolism, thereby reducing 
muscle mass as previously described  [24–27] . In addition, several alterations have a negative 
impact on muscle quality in terms of strength per muscle unit and endurance capacity. The 
latter include muscle fat accumulation that reduces muscle density and quality with lower 
contractile protein content per unit tissue  [35, 53, 54] , mitochondrial dysfunction that may 
cause impaired ATP production, and maximal oxygen consumption leading to both reduced 
strength and endurance  [21] . Physical inactivity that reduces muscle mass, mitochondrial 
biogenesis and function, and tissue lipid oxidation, also leads to reduced strength and 
endurance potentially enhancing tissue and systemic inflammation and oxidative stress  [39, 
40, 55] .
 Skeletal Muscle Changes and Outcome 
 A profound negative clinical impact of low skeletal muscle function and mass is unequiv-
ocally emerging in many disease conditions and in aging  [52, 56, 57] . A similar negative 
impact is also emerging in obesity despite potential difficulties in identifying and defining 
muscle changes within the obese phenotype  [58–60] . Available studies indeed described 
muscle changes through heterogeneous definitions and methodologies including body 
composition analysis, muscle strength, or cardiorespiratory fitness and physical capacity 
 [61–64] . With this limitation in mind, obese individuals with low muscle mass or functional 
parameters had higher risk of developing frailty and disability, and therefore poor quality of 
life  [65, 66] . Risk for frailty and disability in obese individuals with low muscle function and 
mass has been reported to be significantly higher than that observed in non-obese counter-
parts with similar muscle alterations  [65] . This could appear as contradictory to the so-called 
‘obesity paradox’, but it means that obesity does not protect from chronic disease-related 
mortality when it is associated with sarcopenia. Indeed low or declining muscle mass is 
emerging as a negative prognostic factor associated with higher morbidity and mortality in 
obese patients with chronic diseases  [67, 68] . Obese individuals with gastrointestinal cancers 
and low muscle mass accordingly had higher risk of dying than matched obese patients 
without muscle abnormalities  [68] . In obese heart failure patients, low physical capacity also 
predicted poor outcome  [62] . In chronic kidney disease patients, direction of changes in 
muscle mass was the major determinant of survival independently of direction of changes of 
total body weight  [70] . We conclude that i) available evidence, despite limitations and hetero-
geneity, points towards an important role of skeletal muscle changes with altered function 
and mass in negatively modulating obese patient morbidity and mortality; and that ii) 
preventing and/or treating muscle changes has therefore relevant potential to improve 
obesity-associated morbidity and mortality.
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 Where We Are – Sarcopenic Obesity: Limitations and Needs  
 Low muscle function and mass are currently addressed in obese individuals under the 
definition of sarcopenic obesity. The latter is based on the originally geriatric concept of 
sarcopenia, i.e. the age-associated combination of declining muscle mass and function (partic-
ularly muscle strength)  [52] . A definition of primary, age-associated sarcopenia and corre-
sponding diagnostic criteria have been proposed  [52] , but relevant methodological issues 
and clinical thresholds for defining criteria remain under debate. The current definitions of 
sarcopenic obesity combine sarcopenia, as defined through variable criteria, with the presence 
of obesity either defined as BMI > 30 kg/m 2 or by adiposity levels  [61, 71–73] . We believe that 
these concepts and available results represent important starting points, but do not currently 
allow for satisfactory patient identification, clinical stratification, and thus treatment. As a 
direct consequence, awareness of the relevance of skeletal muscle maintenance in obesity 
remains inadequate among researchers and clinicians. We specifically identify the following 
limitations and needs ( table 1 ).
 Basic Knowledge 
 –  Limitations : Although several mediators and metabolic pathways involved in the onset of 
skeletal muscle catabolism and anabolic dysfunction have been elucidated, knowledge 
remains incomplete. 
 –  Needs:  Research should continue to elucidate fundamental issues in terms of molecular 
and endocrine mediators regulating skeletal muscle function and mass as well as amino 
acid metabolism, with particular regard to cross-talk and interactions between skeletal 
muscle and adipose tissue also at stem cell level. Additional important areas include 
mediators of positive effects of exercise, the role of gut hormonal systems and microbiota 
metabolism and their nutritional regulation in altering skeletal muscle homeostasis with 
potential muscle-catabolic systemic alterations [74], the role of brain regulation of 
physical and skeletal muscle activities [75]. Also importantly, research should aim at 
elucidating potential disease-specific mechanisms that could interact with obesity in 
regard to negatively affecting muscle function and mass in the presence of various 
complications and comorbidities. 
 Patient Groups and Clinical Settings 
 –  Limitations:  The concept of sarcopenia and sarcopenic obesity have been primarily 
defined and applied in geriatric populations  [8, 52, 65] . Although the parallel concept of 
secondary sarcopenia was introduced to refer to all-cause early onset of muscle loss and 
dysfunction, we are convinced that substantial work is needed to enhance awareness of 
the strong risk for muscle changes in obese individuals at any age.  
 –  Needs: Awareness of the risk of muscle changes should be particularly promoted at any 
age for obese individuals in the presence of metabolic complications, chronic comorbidities, 
Sarcopenic obesity: limitat ions and needs
Basic knowledge
Diagnostic tools
Diagnostic criteria
Prevention and treatment
Patient subgroup and clinical settings definition
Table 1.  The following areas are 
identified as suffering from 
limitations in knowledge and/or 
consensus and are proposed for 
focused, coordinated action in 
obese individuals with low 
muscle function and mass
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acute or critical illness, and following bariatric surgery or hypocaloric diet. Disability and 
frailty may occur in obese geriatric and non-geriatric patients and should be evaluated 
through medical history and clinical assessment in obese individuals at risk for, or already 
presenting with, clinical comorbidities. It should also be pointed out that patient 
characteristics and therapeutic needs for low muscle function and mass may vary 
substantially in different settings; this fundamental issue should be appropriately 
recognized and addressed.  
 Diagnostic Tools  
 –  Limitations:  As mentioned above, identification of diagnostic tools to measure skeletal 
muscle and fat mass as well as skeletal muscle function has proven generally problematic, 
particularly in terms of combining precision, safety, and routine applicability in clinical 
practice. It should be pointed out that simple anthropometric measurements may be 
biased in obese individuals by confounding adipose depots. Radiological methodologies 
that include nuclear magnetic resonance spectroscopy, selected CT scans or dual energy 
X-ray absorptiometry (DEXA) have been considered potentially most accurate but are 
not readily available and may involve X-ray exposure  [64] . Bioelectrical impedance 
analysis has been considered and proposed as a potential acceptable compromise in 
terms of invasiveness, accuracy, and applicability in the absence of confounding fluid 
balance abnormalities  [76, 77] . Functional measures also are heterogeneous and include 
hand-grip, knee extensor strength, and various mobility measurements involving postural 
or walking tests  [64] . 
 –  Needs: There is obviously no ideal methodology to simultaneously achieve maximal 
precision, safety, and routine applicability. Since the latter is ultimately sought, surrogate 
markers may have to be accepted as reasonable compromises (e.g. as similarly applied 
for waist circumference relative to abdominal visceral fat). To reach larger consensus on 
diagnostic tools, homogeneous datasets should be ideally evaluated or created to identify 
gold standard techniques and corresponding acceptable, readily applicable surrogate 
markers. Although apparently adding to complexity, such efforts should also aim at 
evaluating homogeneous patient groups, and potential different optimal approaches in 
different patient groups should be considered. 
 Diagnostic Criteria  
 –  Limitations:  Diagnostic criteria for obesity with low muscle function and mass currently 
suffer from lack of widespread consensus on diagnostic tools and related difficulties in 
comparing different outcome measures in different studies  [61, 71–73] . Normalization 
of available outcomes into indexes attempting to normalize measured information may 
be appropriate, but it also may result in enhanced variability. Application of different 
criteria to identify sarcopenic obesity may therefore currently lead to substantially and, 
unfortunately, clinically unacceptable variable prevalence levels. 
 –  Needs:  Overcoming lack of consensus will likely require further evaluation or creation of 
databases that should be ideally acquired in the context of homogeneous methodologies 
and designs. Systematic efforts to integrate measurements of both muscle and fat mass 
and their relationships, as well as their body distribution, in the concept of sarcopenic 
obesity are also missing  [77, 78] . We believe that such efforts should also be undertaken, 
based on evidence of fundamental pathogenetic inter-relationships between adipose and 
skeletal muscle mass, distribution, and function.  
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 Prevention and Treatment 
 –  Limitations:  Under the above-described conditions it is perhaps not surprising that 
prevention and treatment of low muscle function and mass in obese individuals are both 
difficult and under-implemented. Multimodal therapeutic strategies should include 
physical activity and nutrition  [79–82] that should in turn offers adequate high-quality 
protein intake  [83, 84] or protein / amino acid administration in patients in need of 
medical nutrition  [83–85] . As previously discussed, heterogeneity in patients groups, 
treatment protocols, and outcome measures make it difficult to compare and interpret 
study results. Use of nutraceuticals to stimulate anabolism beyond anabolic resistance 
has also been advocated and tested, but variable protocols, treatment duration, and dose 
prevent final conclusions on their efficacy  [86] . 
 –  Needs: Identification of optimal prevention and treatment modalities aimed at preserving 
and increasing skeletal muscle function and mass in obesity is of urgent priority, and 
potential use of nutraceuticals besides optimal macronutrient composition should be 
specifically addressed  [86] . It should however be pointed out that, despite gaps and 
limitations in knowledge, a large and growing body of evidence provides strong support 
for an association of protein and amino acid intake as well as skeletal muscle anabolism 
with maintenance of lean body mass  [83, 84] . It therefore seems that routinely 
recommending and ensuring adequate protein intake of 1 g/kg ideal body weight per day 
as recommended intake in healthy non-geriatric populations is reasonable and safe, with 
higher amounts for high-risk patient groups in the absence of contraindications (see 
paragraph below). We also need to emphasize that exercise training or physical therapy 
have repeatedly been proven effective in improving muscle function and mass, and 
appropriate and safe exercise levels relative to the level of comorbidities and disabilities 
should be routinely recommended in obese patients  [80–82] . 
 Current Approach – What We Can Do 
 We are aware that existing limitations in current approaches to obese individuals with 
low muscle function and mass must not limit our efforts to provide the best possible clinical 
assessment and treatment. We propose the following approaches:
 –  Awareness:  We believe that risk of skeletal muscle loss and dysfunction should be 
considered in obese patients, particularly in the presence of advanced age (>65 years) or 
when concomitant metabolic complications, chronic diseases, or acute complications 
occur. Efforts should be made to monitor skeletal muscle function and mass and to 
prevent or minimize its loss in patients undergoing bariatric surgery procedures, with 
particular regard to malabsorptive ones, and in those undergoing hypocaloric dietary 
treatment particularly in the presence of advanced age and/or comorbidities. It may also 
concern patients recovering from critical illness or after long immobilization as in ICU 
 [48] , as well as patients suffering from specific endocrine disorders (diabetes, 
hypogonadism, Cushing syndrome, or long-term glucocorticoid treatment). 
 –  Assessment – Skeletal Muscle Function and Mass, Functional Status and Disabilities: When 
loss of skeletal muscle mass and/or function is suspected or appears likely based on 
medical history and examination, clinical assessment should include measurement of 
body composition and muscle strength by available techniques, such as bioelectrical 
impedance analysis, handgrip test or walking test. Such information may be useful not 
only for identification of muscle changes but also for longitudinal patient monitoring 
over time. We support the concept that global assessment of obese individuals should 
include functional status, particularly in the presence of complications and comorbidities. 
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The recently proposed Edmonton obesity staging system  [87] provides a potential 
example of staging tools including disability assessment that may in turn largely reflect 
loss of skeletal muscle function and mass. Presence of components of frailty could also be 
assessed to the same purpose not only in elderly individuals but in all at-risk patients.  
 –  Prevention and Treatment – Nutrition and Physical Activity: In patients with clinical 
evidence for loss of skeletal muscle function and mass or in those with at-risk conditions 
such as metabolic complications, chronic and acute disease and advanced age as well as 
in those undergoing weight loss programs, treatment should be associated with 
precautions to prevent, limit, or treat skeletal muscle alterations. Such approaches should 
include nutritional care and physical exercise. Based on available evidence  [83, 84] , 
adequate protein intake of 1 g/kg ideal body weight per day should be provided in healthy 
non-geriatric individuals. In addition, higher protein intakes are increasingly 
recommended by guidelines and expert groups for high-risk patients. The latter include 
aged individuals and hemodialysis patients  [83] . Obese ICU patients undergoing acute 
metabolic stress with likely substantial muscle loss and weakness have been specifically 
addressed in recent guidelines with recommendations of very high protein intakes of up 
to 2.2 g/kg day through medical nutritional support  [84] . Hypocaloric diets with 
unbalanced macronutrient composition and higher protein levels are considered 
acceptable by recent guidelines  [15, 16] and could become more routinely recommended 
particularly in patients with low muscle function and mass in need to undergo weight 
loss treatment, or in those at higher risk of developing such changes during weight loss. 
Oral protein supplements should be considered when sufficient dietary intake is not 
possible  [88] . As previously anticipated, appropriate and safe exercise levels relative to 
comorbidities and disabilities should be routinely implemented. Physical support 
rehabilitation should finally be implemented whenever possible according to patient 
status  [89] . 
 Conclusion: A Call for Action 
 The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European 
Association for the Study of Obesity (EASO) recognize and indicate obesity with altered body 
composition due to low skeletal muscle function and mass (sarcopenic obesity) as a scientific 
and clinical priority. ESPEN and EASO therefore call for coordinated action aimed at increasing 
awareness on this topic among researchers and clinicians, and at promoting research and 
initiatives aimed at reaching evidence-based consensus on diagnostic tools, definition, and 
diagnostic criteria as well as optimal treatment. ESPEN and EASO aim at directly contributing 
by promoting the topic in workshops, meeting sessions and educational initiatives, by 
fostering networking and collaboration among interested scientists and experts, and by 
promoting awareness and disseminating evidence on best available diagnostic tools and on 
treatment options with particular regard to diet and medical nutritional support. We are 
convinced that achievement of these goals has a strong potential to reduce the burden of 
morbidity and mortality in the dramatically increasing obese patient population across all 
medical specialties.
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